You are here: Industry Insights > inhibitor

News List

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA PR NEWSWIRE
November 22, 2024
Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China PharmaSources
November 15, 2024
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China PharmaSources
September 19, 2024
InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.
Atriva Therapeutics announces publication of Proof of Concept (POC) / Phase 2a RESPIRE study data with zapnometinib in patients hospitalized with COVID-19 B3C newswire
November 06, 2023
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today the publication of proof-of-concept data for its oral MEK inhibitor.
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting PharmaSources
April 18, 2023
April 18, 2023，Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China PharmaSources
March 10, 2023
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 inhibitor ICP-248 in China.
WHO recommends two new drugs to treat patients with COVID-19 WorldPharmaNews
January 18, 2022
The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids...
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 drugs.com
January 18, 2022
The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19...
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA prnasia
January 17, 2022
Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate...
Eisai, Gilead Enter Exclusive Agreement for JAK Inhibitor Filgotinib in Asia contractpharma
December 22, 2021
Eisai obtains exclusive marketing right for filgotinib in South Korea, Taiwan, China, Hong Kong, S.A.R., China and Singapore and will take over manufacturing and marketing.